𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Xanthohumol inhibits inflammatory factor production and angiogenesis in breast cancer xenografts

✍ Scribed by Rosário Monteiro; Conceição Calhau; Artur Oliveira e Silva; Sandra Pinheiro-Silva; Susana Guerreiro; Fátima Gärtner; Isabel Azevedo; Raquel Soares


Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
212 KB
Volume
104
Category
Article
ISSN
0730-2312

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Xanthohumol (XN), a natural polyphenol present in beer, is known to exert anti‐cancer effects. However, its precise mechanisms are not yet clearly defined. The aim of this study was to investigate the effect of oral administration of XN in breast cancer xenografts in nude mice. Proliferation and apoptosis were first examined in MCF7 cell cultures after incubation with XN by trypan blue exclusion assay, [^3^H]‐thymidine incorporation, KI67 immunostaining and TUNEL. Morphological and histological characteristics of tumours from XN‐treated or control (vehicle‐treated) mice were compared. Immunohistochemistry for proliferative, inflammatory and endothelial cell markers was performed and activation of nuclear factor kappa B (NFκB) pathway was assessed by ELISA. In vitro MCF7 cell proliferation decreased in a dose‐dependent manner. Oral administration of XN to nude mice inoculated with MCF7 cells resulted in central necrosis within tumours, reduced inflammatory cell number, focal proliferation areas, increased percentage of apoptotic cells and decreased microvessel density. Anti‐angiogenic effects of XN were further confirmed by immunoblotting for factor VIII expression in XN‐treated tumours as compared to controls. Decreased immunostaining for NFκB, phosphorylated‐inhibitor of kappa B and interleukin‐1β were also observed as well as a significant decrease in NFκB activity to 60% of control values. These novel findings indicate that XN is able to target both breast cancer and host cells, namely inflammatory and endothelial cells, suggesting its potential use as a double‐edge anti‐cancer agent. J. Cell. Biochem. 104: 1699–1707, 2008. © 2008 Wiley‐Liss, Inc.


📜 SIMILAR VOLUMES


Inhibition of angiogenesis and breast ca
✍ Yifan Zhai; Jingyi Yu; Luisa Iruela-Arispe; Wei-Qun Huang; Zheng Wang; Andrew J. 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 French ⚖ 122 KB 👁 1 views

Recently, we reported a novel protein of the tumor necrosis factor (TNF) superfamily, named vascular endothelial cell growth inhibitor (VEGI), which is expressed predominantly in endothelial cells. When a secreted form of this new protein was overexpressed in mouse colon cancer cells, the growth of

Expression of growth factors, growth-inh
✍ de Jong, Johannes S.; van Diest, Paul J.; van der Valk, Paul; Baak, Jan P. A. 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 56 KB 👁 2 views

Growth factors may play an important role in tumour growth and angiogenesis by their influence on tumour cell proliferation or their effect on neovascularization. The aim of the present study was to determine which of the growth factors, growth-inhibiting factors, and their receptors investigated in

Knock-down of amphiregulin inhibits cell
✍ Andrea Baillo; Craig Giroux; Stephen P. Ethier 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 456 KB

## Abstract We have previously shown that SUM‐149 human breast cancer cells require an amphiregulin (AREG) autocrine loop for cell proliferation. We also demonstrated that AREG can increase epidermal growth factor receptor (EGFR) stability and promote EGFR localization to the plasma membrane. In th

Angiogenesis in breast cancer: The role
✍ Chenggang Li; Baoqiang Guo; Carmelo Bernabeu; Shant Kumar 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 486 KB 👁 1 views

The progression of breast cancer depends on the establishment of a neovasculature, by a process called angiogenesis. Angiogenesis is an invasive cellular event that requires the co-ordination of numerous molecules including growth factors and their receptors, extracellular proteins, adhesion molecul